175 related articles for article (PubMed ID: 29891610)
1. Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
Ankrom W; Yee KL; Sanchez RI; Adedoyin A; Fan L; Marbury T; Preston RA; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891610
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
[TBL] [Abstract][Full Text] [Related]
4. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
Khalilieh S; Yee KL; Liu R; Fan L; Sanchez RI; Auger P; Triantafyllou I; Stypinski D; Lasseter KC; Marbury T; Iwamoto M
J Clin Pharmacol; 2017 Jun; 57(6):777-783. PubMed ID: 28026013
[TBL] [Abstract][Full Text] [Related]
5. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
Behm MO; Yee KL; Fan L; Fackler P
Antivir Ther; 2017; 22(4):337-344. PubMed ID: 28206979
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M
Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220
[TBL] [Abstract][Full Text] [Related]
8. Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Khalilieh S; Yee KL; Sanchez RI; Triantafyllou I; Fan L; Maklad N; Jordan H; Martell M; Iwamoto M
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872071
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1.
Yee KL; Ouerdani A; Claussen A; de Greef R; Wenning L
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745394
[TBL] [Abstract][Full Text] [Related]
10. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
[TBL] [Abstract][Full Text] [Related]
11. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
Behm MO; Yee KL; Liu R; Levine V; Panebianco D; Fackler P
Clin Drug Investig; 2017 Jun; 37(6):571-579. PubMed ID: 28349328
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
Matthews RP; Jackson Rudd D; Fillgrove KL; Zhang S; Tomek C; Stoch SA; Iwamoto M
Clin Drug Investig; 2021 Jul; 41(7):629-638. PubMed ID: 34151413
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
Schürmann D; Sobotha C; Gilmartin J; Robberechts M; De Lepeleire I; Yee KL; Guo Y; Liu R; Wagner F; Wagner JA; Butterton JR; Anderson MS
AIDS; 2016 Jan; 30(1):57-63. PubMed ID: 26372481
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.
Sanchez RI; Yee KL; Fan L; Cislak D; Martell M; Jordan HR; Iwamoto M; Khalilieh S
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):107-114. PubMed ID: 30973682
[TBL] [Abstract][Full Text] [Related]
19. A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Vaynshteyn K; Deschamps K; Martell M; Jordan HR; Iwamoto M
J Clin Pharmacol; 2019 Aug; 59(8):1093-1098. PubMed ID: 30817001
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Sanchez RI; Fillgrove KL; Yee KL; Liang Y; Lu B; Tatavarti A; Liu R; Anderson MS; Behm MO; Fan L; Li Y; Butterton JR; Iwamoto M; Khalilieh SG
Xenobiotica; 2019 Apr; 49(4):422-432. PubMed ID: 29557716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
